New combo therapy aims to control advanced breast cancer longer
NCT ID NCT07195227
Summary
This study is testing whether combining two drugs, camizestrant and ribociclib, can better control advanced hormone-positive breast cancer. It will involve about 150 adults whose cancer has progressed despite at least 5 years of prior hormone-blocking therapy. The main goal is to see if this combination can delay the cancer from getting worse for a longer period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.